CD209

Across TCGA pan-cancer cohorts, CD209 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD209 data layer compared with 17 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD209 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CD209 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where CD209 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.674	0.427	.025	8	view →
LUAD	DFS	Tertile	All	0.805	0.363	.001	8	view →
LSCC	OS	Median	II,III,IV	0.896	1.000	.013	7	view →
HNSC	DFS	Quartile	All	0.874	0.988	.019	6	view →
CCRCC	OS	Median	II,III,IV	0.289	1.000	.011	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD209–PDAC (OS)

Open the PDAC breakdown →